News of Note—McKesson relaunches pharma services


Here is some news of note for the week: 

 > McKesson has relaunched its biopharmaceutical services business. Release

> The EMA says it may seek to order fluoroquinolone and quinolone antibiotics off the market following a review of disabling and potentially long-lasting side effects. Announcement


Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

> Vetter is expanding its secondary packaging operations, adding a second building to its Ravensburg site which will be ready in 2020. Release


Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.